title: Endophthalmitis outbreak associated with repackaged bevacizumab.
authors.forename: Laura S
authors.initials: LS
authors.lastname: Edison
authors.forename: Hope O
authors.initials: HO
authors.lastname: Dishman
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: Tobin-D'Angelo
authors.forename: C Richard
authors.initials: CR
authors.lastname: Allen
authors.forename: Alice Y
authors.initials: AY
authors.lastname: Guh
authors.forename: Cherie L
authors.initials: CL
authors.lastname: Drenzek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D056568:Carnobacteriaceae / Q000302:isolation & purification; D004196:Disease Outbreaks; D004340:Drug Contamination; D009877:Endophthalmitis / Q000453:epidemiology* / Q000382:microbiology; D005260:Female; D005845:Georgia / Q000453:epidemiology; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology* / Q000382:microbiology / Q000635:transmission; D006801:Humans; D007196:Indiana / Q000453:epidemiology; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D056687:Off-Label Use; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab